Medarex, Inc. to Receive Milestone Payment from FibroGen, Inc. for the Initiation of a Phase 2 Study of FG-3019 in Patients with Diabetic Kidney Disease

Published: Jul 13, 2009

PRINCETON, N.J.--(BUSINESS WIRE)--Medarex, Inc. (NASDAQ:MEDX) today announced it will receive a milestone payment of an undisclosed amount from its licensing partner, FibroGen, Inc., in connection with a recently initiated Phase 2 clinical trial of FG-3019 in patients with type 2 diabetes and advanced kidney disease as announced by FibroGen on June 15, 2009.

Back to news